Hematology

Treatment-naive transformed DLBCL shows worse PFS driven by early progression.

In a propensity score–matched analysis of 1735 treatment-naive DLBCL patients, trDLBCL had significantly worse PFS (HR 1.754, p<0.001). The excess risk reflected early progression (POD24 30.56% vs 18.52%; OR 1.94), while CNS involvement was low and similar between groups. Overall survival was comparable after salvage therapies, but patients with “pure transformation” had markedly poorer PFS and higher mortality risk. These observational data support closer early surveillance and testing of risk-adapted frontline or consolidation strategies for trDLBCL. 1

Early-phase plasma cell dyscrasia abstracts under-report toxicities and minimize harms.

Among 250 phase I PCD abstracts, only 70.4% reported all-grade toxicity, 80% reported grade ≥3, and 36.8% reported deaths. Minimizing language appeared in 77.6% of abstracts and often accompanied high AE rates and treatment discontinuations. Reporting varied by sponsor type, timing, and agent class, reducing transparency for safety assessment and trial interpretation. These findings argue for mandatory minimum toxicity reporting standards in early-phase hemato-oncology abstracts. 2

Restrictive transfusion strategy did not significantly reduce death or death/MI in AMI with anemia.

Subanalysis of MINT (n=3504; 1679 critically ill) compared restrictive (Hb threshold 7–8 g/dL) versus liberal (Hb 10 g/dL) strategies. Restrictive transfusion produced nonsignificant increases in death (critically ill RR 1.24, 95% CI 0.95–1.61) and death/MI (RR 1.21, 95% CI 0.99–1.47). Critically ill patients had higher absolute event rates (death 11.9% vs 6.5%; death/MI 18.9% vs 12.7%). No interaction by ICU status was detected; apply transfusion thresholds individualized to ischemic risk and clinical context. 3